Article downloads are temporarily unavailable, affecting member access to articles and purchased articles. Thank you for your patience. For immediate assistance contact ONS
cancel
Mantovani, G., Macciò, A., Madeddu, C., Gramignano, G., Lusso, M. R., Serpe, R., . . . Deiana, L. (2006). A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiology, Biomarkers and Prevention, 15, 1030–1034.
The integrated treatment consisted of the following components:
High polyphenols content (400 mg)
Antioxidant treatment (300 mg/d a-lipoic acid + 2.7 g/d carbocisteine lysine salt + 400 mg/d vitamin E + 30,000 IU/d vitamin A + 500 mg/d vitamin C)
Pharmaconutritional support enriched with 2 cans per day (n-3) polyunsaturated fatty acids (PUFA) (eicosapentaenoic acid and docosahexaenoic acid), 500 mg/d medroxyprogesterone acetate, and 200 mg/d selective cyclooxygenase-2-inhibitor celecoxib.
Patient outcomes were assessed at baseline and one, two, and four months.
Sample Characteristics
The sample included 39 patients with cancer-related anorexia/cachexia syndrome (CACS).
Mean age was 58.9 years (range 42–78).
The majority of patients were male (n = 23).
Patients had multiple tumor sites, but the most common was head and neck (43.6%); 97.4% were stage IV.
Setting
Not identified
Phase of Care and Clinical Applications
Patients were undergoing the active treatment phase of care.
Study Design
This was an open, early-phase II study.
Measurement Instruments/Methods
Multidimensional Fatigue Symptom Inventory–Short Form (MFSI-SF)
Results
Compared to baseline scores, fatigue outcomes improved at two months (p = 0.22) and more so at four months (p = 0.004). No correlation existed between changes in fatigue and changes in any other variable studied.